Krystal Biotech (KRYS) – Research Analysts’ Recent Ratings Changes
A number of research firms have changed their ratings and price targets for Krystal Biotech (NASDAQ: KRYS): 9/24/2026 – Krystal Biotech was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”. 9/24/2026 – Krystal Biotech is now covered by The Goldman Sachs Group, Inc.. They set a “buy” rating and a $441.00 price target […]
30 Sep 22:56 · The Markets Daily